ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe allergic reactions that can lead to anaphylaxis, today announced the appointment of Donn Casale as President, effective June 1, 2026. Richard Lowenthal will continue to lead ARS Pharma as Chief Executive Officer.

https://www.globenewswire.com/news-release/2026/05/13/3293945/0/en/ars-pharmaceuticals-strengthens-leadership-team-with-appointment-of-industry-veteran-donn-casale-as-president.html